A single institution experience with peptide receptor radionuclide therapy (PRRT) in advanced pheochromocytoma and paraganglioma

#3248

Introduction: Pheochromocytomas and parangliomas (PPGLs) are very rare tumors. Due to their heterogenicity, there is a lack of treatment guidelines, and therapy options generally are very limited.

Aim(s): We present our experience with peptide receptor radionuclide therapy (PRRT) in advanced PPGL.

Materials and methods: Six patients (1 woman, 5 men; mean±SD: 59.7±11.7years-old) with progressive, somatostatin receptor (SSR)-expressing PPGLs: 4 paragangliomas, and 2 pheochromocytomas were treated with 177Lu-DOTATATE. 68Ga-DOTATATE PET was obtained at baseline, after 2 cycles, and after 4 cycles. Follow-up imaging was performed every 3 months. Laboratory tests were performed 1 week before each cycle and every 2 months at follow-up. The median follow-up since PRRT initiation was 22±6 months. Toxicity was determined based on NCI CTCAE V5.0. Overall response rate (ORR) was determined.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Duan H

Authors: Duan H, Ferri V, Fisher G, Shaheen S, Davidzon G,

Keywords: paraganglioma, pheochromocytoma, PRRT, 177Lu-Dotatate,